LIQUIDIA CORP (LQDA)
Sector: Health Care
2026 Annual Meeting Analysis
LIQUIDIA CORP · Meeting: June 16, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class II Directors to Serve for a Term Expiring at the 2029 Annual Meeting
No overboarding, no attendance issues, and LQDA's 3-year total shareholder return of +450% is roughly 408 percentage points above the peer group median of +43%, far exceeding the 50-percentage-point threshold required to trigger a concern under the strong-positive TSR tier — strong performance throughout her tenure.
No overboarding, no attendance issues, and LQDA's exceptional 3-year stock performance vastly outperforms the peer group median, clearing the TSR trigger threshold with no concerns.
No overboarding, no attendance issues, and LQDA's 3-year total shareholder return of +450% compared to a peer median of +43% represents outperformance of +408 percentage points, well above the 50-point underperformance threshold needed to trigger a concern — shareholders have been well served during his tenure.
All three Class II director nominees — Katie Rielly-Gauvin, Ramandeep Singh, and David Johnson — pass all policy screens. LQDA's 3-year total shareholder return of +450% is +408 percentage points above the company-disclosed peer group median of +43%, which under the strong-positive TSR tier requires underperformance of at least 50 percentage points to trigger a concern. No overboarding, attendance deficiencies, independence issues, or familial relationship flags were identified. All three nominees receive a FOR vote.
Say on Pay
✓ FORCEO
Roger A. Jeffs, Ph.D.
Total Comp
$7,712,736
Prior Support
97.1%%
CEO total compensation of $7.7 million is reasonable for a biotech CEO leading a company with a $3.3 billion market cap, a landmark commercial drug launch, and one of the top specialty drug launches in recent years across all therapeutic categories. Pay mix is heavily variable — roughly 73% of total CEO pay came from stock awards and performance-based cash bonuses, well above the 50-60% variable pay threshold the policy requires. The performance-based bonuses paid at the 200% maximum level are directly supported by the company's exceptional 2025 results: FDA approval, commercial launch, profitability achieved within one quarter of launch, and a stock price that rose 166% in one year, far outpacing both the XBI sector ETF benchmark (+6.8% over the past year) and the company's disclosed peer group (+18% median). Prior-year Say on Pay support was 97.1%, reflecting strong shareholder alignment, and a meaningful clawback policy compliant with Nasdaq listing standards is in place.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
N/A
Audit Fees
$900,000
Non-Audit Fees
$2,000
Non-audit fees of $2,000 represent only 0.2% of audit fees of $900,000, well below the 50% threshold that would raise independence concerns; no material restatements were disclosed; and PricewaterhouseCoopers LLP is a Big 4 firm appropriate for a $3.3 billion market cap company. Auditor tenure was not disclosed in the proxy, but policy requires confirmed data to trigger a no vote, so no tenure concern is raised.
Overall Assessment
Liquidia Corporation's 2026 annual meeting ballot contains three standard proposals: director elections, auditor ratification, and Say on Pay. All three receive a FOR vote — the company delivered exceptional shareholder returns over the past 1, 3, and 5 years, director nominees pass all policy screens, auditor fees are clean with negligible non-audit work, and executive compensation is well-structured with strong pay-for-performance alignment backed by a landmark commercial drug launch.
Compensation Peer Group
14 companies disclosed in 2026 proxy filing